It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Rybelsus: Novo Nordisk’s name-brand version of oral semaglutide tablets to help improve blood sugar levels (along with diet ...

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

In recent years, interest in these medications—initially developed to treat type 2 diabetes—has exploded ... for GLP-1 ...

The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation ...